{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2","upperLimit":"41","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"The duration of response is measured from the time a participant achieved a response until the date of progression.","dispersionType":"Full Range","groups":[{"description":"\\- IDR The study treatment will consist on an induction and a maintenance phase. Dose modification will be permitted for toxicity\n\n* Induction cycles will be 4 weeks long, Maintenance cycles 8 weeks long.\n* Ixazomib- administered orally on predetermined days and dosage during Induction and Maintenance Phase\n* Dexamethasone- administered via IV or orally on predetermined days and dosage during Induction and Maintenance Phase\n* Rituximab- administered via IV on predetermined days and dosage during Induction and Maintenance Phase\n\nIxazomib: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.\n\nDexamethasone: Doses given on Days 1, 8, and 15 in induction and maintenance cycles.\n\nRituximab: Doses given on Day 1 of induction and maintenance cycles.","id":"OG000","title":"Ixazomib, Dexamethasone, Rituximab"}],"paramType":"MEDIAN","populationDescription":"All participants who achieved a response to therapy.","reportingStatus":"POSTED","timeFrame":"From the time each participant achieved a response to time of disease progression, assessed up to 4 years after treatment start","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"months"}